Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marisa Hill, MD
Loxo Oncology, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
232 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Canberra Hospital
Garran, Australian Capital Territory, Australia
- St Vincent'S Hospital
Darlinghurst, New South Wales, Australia
- the St. George Hospital
Kogarah, New South Wales, Australia
- Ingham Institute of Medical Research
Liverpool, New South Wales, Australia
- Westmead Hospital
Wentworthville, New South Wales, Australia
- the Alfred Hospital
Melbourne, Victoria, Australia
- Royal Perth Hospital
Perth, Western Australia, Australia
- Uniklinikum Salzburg
Salzburg, Osterreich, Austria
- Ordensklinikum Linz Gmbh Elisabethinen
Linz, Upper Austria, Austria
- Medizinische Universität Wien
Vienna, Austria
- Chr Verviers-Onco
Verviers, Liege, Belgium
- Vitaz
Sint-Niklaas, Oost-Vlaanderen, Belgium
- Az Delta
Roeselare, West Flanders, Belgium
- Universitair Ziekenhuis Gent
Ghent, Belgium
- Groupe Jolimont
Haine-Saint-Paul, Belgium
- Az St-Elisabeth
Herentals, Belgium
- Clinique Saint Pierre Ottignies
Ottignies, Belgium
- Cancer Care Manitoba
Winnipeg, Manitoba, Canada
- Queen Elizabeth Ii Health Sciences Center
Halifax, Nova Scotia, Canada
- Southlake Regional Health Centre
Newmarket, Ontario, Canada
- Princess Margaret Hospital (ontario)
Toronto, Ontario, Canada
- Peking University First Hospital
Beijing, Beijing Municipality, China
- Peking University Third Hospital
Beijing, Beijing Municipality, China
- Xuanwu Hospital Capital Medical University
Xicheng District, Beijing Municipality, China
- Gansu Province Cancer Hospital
Lanzhou, Gansu, China
- Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- Hainan Province People'S Hospital
Haikou, Hainan, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- Hunan Cancer Hospital
Changsha, Hunan, China
- the Affiliated Hospital of Xuzhou Medical College
Xuzhou, Jiangsu, China
- the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
- the Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
- Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
- Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
- Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
- Zhejiang Provincial Taizhou Hospital
Linhai, Zhejiang, China
- Beijing Hospital
Beijing, China
- Fudan University Shanghai Cancer Center
Shanghai, China
- Shanghai Jiaotong University School of Medicine Ruijin Hospital
Shanghai, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Mar 2021
- Primary completion
- 29 Aug 2023
- Completion
- 31 May 2027
- Last update posted
- 24 Apr 2026
- Registered enrollment
- 238
- Registry id
- NCT04666038
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.